TRAIL promotes hepatocellular carcinoma apoptosis and inhibits proliferation and migration via interacting with IER3

Table 3 Univariate and multivariate analyses of various prognostic parameters in patients with HCC Cox-regression analysis

	Univariate analysis			Multivariate analysis
	p value	Hazard Ratio	95% confidence interval	p value	Hazard Ratio	95% confidence interval
IER3	0.041	0.549	0.305–0.989	0.046252	0.596	0.246–1.444
Gender (male/female)	0.241	0.496	0.153–1.601	0.048	0.168	0.029–0.983
HBsAg (positive/negative)	0.906	1.045	0.502–2.175	0.037	0.276	0.082–0.924
GGT (U/L, < 40 vs. ≥ 40)	0.034	2.148	1.059–4.356	0.017	4.274	1.300–14.054
Cirrhotic nodules (single/multiple)	0.121	3.077	0.745–12.713	0.033	12.069	1.216–119.809
AJCC TNM stage (I + II vs III + IV)	0.021	4.115	1.237–13.688	0.857	0.792	0.062–10.152

Italics numbers indicate significant differences (P < 0.05)
HCC hepatocellular carcinoma, HBsAg hepatitis B surface antigen, GGT Gamma-Glutamyltransferase, AJCC the American Joint Committee on Cancer, TNM tumor-node-metastasis

ISSN: 1475-2867